Zhao Songji
Updated:
Affiliation
Radiotheranostic Development Unit （Radiation science, medicine and drug development, & industrial applications for radiation）
Position
Chief Senior Researcher
Final Education
Completed Hokkaido University, Doctoral Course, Graduate School of Medicine
Degree(s)
PhD.(Medicine)
Research Keywords
Targeted Alpha particle Therapy (TAT), Astatine-211, Astatine-211-labeled Antibody, Theranostics, Nuclear Medicine Therapy
Research Area
Nuclear Medicine, Molecular imaging
External Link
Academic Affiliations
- The Japanese Society of Nuclear Medicine (JSNM)
- Japanese Society for Molecular Imaging, The Society for Small Animal In Vivo Imaging (CSAI)
- The Society of Nuclear Medicine and Molecular Imaging (SNMMI)
- World Molecular Imaging Congress (WMIC)
- Radiological Society of North America (RSNA)
No information.
Patents / Industrial Property Rights
- Patent Publication No. 2024-007524: Alpha-emitting nuclide-labeled anti-CD82 antibody
- Patent Application No. 2025-117536: Humanized anti-CD82 antibody or its fragment
Peer-Reviewed Papers
- Joho T, Zhao S*(Corresponding author), Nishijima K, Ukon N, Shimoyama S, Yamashita A, Washino K, Higashi T, Kobayakawa M, Shiga T, Takahashi K, Ito H, Extended single-dose toxicity study of [211At]meta-astatobenzylguanidine in normal mice in preparation for the first-in-human clinical trial of targeted alpha therapy for pheochromocytoma and paraganglioma, Ann Nucl Med, 39(9), 994-1013, 2025. doi: 10.1007/s12149-025-02065-0.
- Oriuchi N, Aoki M, Ukon N, Washiyama K, Shimoyama S, Nishijima K, Takahashi K, Ito H, Ikezoe T, Zhao S*(Last author), Feasibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using 211At-CXCR4 monoclonal antibody, Sci Rep., 10(1), 6810 2020. doi: 10.1038/s41598-020-63557-9
- Zhao S*(First author/Corresponding author), Yu W, Ukon N, Tan C, Nishijima K, Shimizu Y, Kei Higashikawa, Shiga T, Yamashita H, Tamaki N, Kuge Y, Elimination of tumor hypoxia by eribulin demonstrated by 18F-FMISO hypoxia imaging in human tumor xenograft models, EJNMMI Research. 9(1):51, 2019. doi: 10.1186/s13550-019-0521-x
Books
- Nishijima K, Zhao S, Feng F, Shimizu Y, Akizawa H, Ohkura K, Tamaki N, Kuge Y, Preclinical Evaluation of a Thymidine Phosphorylase Imaging Probe, [123I]IIMU, for Translational Research, Perspectives on Nuclear Medicine for Molecular Diagnosis and Integrated Therapy. Springer Open, 125-130, 2016.
Lectures / Oral Presentations, etc.
- Evaluation of the potential of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using 211At-CD82 monoclonal antibody in a murine xenograft model. SNMMI2024 Annual Meeting, Toronto, Jun 8-11, 2024.
- Current Status and Future Prospects of Preclinical Development of Targeted Alpha Particle Therapy using 211At at Fukushima Medical University. International Symposium on Development of Radiotheranostics in Fukushima. Minamisoma, Fukushima, January 28-29, 2023.
Awards
- FIRST PLACE POSTE – Oncology, Basic Science: at the 67th Annual Meeting of the SNMMI advancing Molecular Imaging and Therapy Virtual Edition. Gold Award winning poster title: Effects and safety of alpha-emitting meta-211At-astato-benzylguanidine (211At-MABG) compared with 131I-meta-iodobenzylguanidine (131I-MIBG) on tumor growth suppression in a pheochromocytoma mouse model. SNMMI2020 Annual Meeting, New Orleans, Jul 11-14, 2020.
No information.
No information.